Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients.

Bui KQ, Ambrose PG, Nicolau DP, Lapin CD, Nightingale CH, Quintiliani R.

Because patients with cystic fibrosis (CF) have pulmonary exacerbations secondary to multi-antibiotic-resistant Gram-negative bacilli, antibiotics, like meropenem, are often utilized. We studied the pharmacokinetics of meropenem (2 g i.v. administered every 8 h in clinically stable CF patients to determine if the recommended maximum doses could sustain adequate concentrations during the dosing interval. These pharmacokinetic data were similar to those obtained in non-CF populations. Using this regimen, concentrations of meropenem exceed the susceptibility breakpoint (4 microg/ml) for 50% of the dosing interval, and therefore provide optimization of the pharmacodynamic profile of the compound. Copyright 2001 S. Karger AG, Basel

For more information about this article, please contact:
Info-ICPD@OrdwayResearch.org